DSS’s Impact BioMedical Announces Second US Patent Issued for its Proprietary Equivir Compound
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced the issuance of Patent # 11,033,528 for its antiviral compound Equivir on June 15, 2021. This patent follows the initial patent granted in 2019. Equivir has shown positive pre-clinical results against viral infections including Ebola and Rhinovirus. The company is pursuing a third patent and aims to explore its potential in various antiviral applications, enhancing its intellectual property portfolio.
- The second patent for Equivir expands Impact BioMedical's intellectual property.
- Equivir has demonstrated positive pre-clinical results against Ebola and Rhinovirus.
- None.
ROCHESTER, N.Y., July 12, 2021 (GLOBE NEWSWIRE) -- Impact BioMedical Inc., a wholly owned subsidiary of Document Security Systems Inc. (NYSE American: DSS), today announced it was issued a patent (Patent # 11,033,528) on June 15, 2021, from the U.S. Patent and Trademark Office for its proprietary compound Equivir. This is a follow-up to the release on April 6, 2021, for the allowance of this patent. The compound has displayed positive pre-clinical results that reduce the risk and/or severity attributable to viral infections, specifically Ebola and Rhinovirus.
This patent is the second issued to Impact BioMedical for Equivir; the first (Patent # 10,383,842) was issued August 20, 2019, with claims directed to a method of limiting the occurrence of, reducing the risk or severity of, or treating influenza infection.
“This is the second patent for Equivir and expands Impact BioMedical’s intellectual properties in this area,” said Frank D. Heuszel, CEO of DSS. “We are seeking a third patent for Equivir, with the hope of expanding its potential in a variety of antiviral applications and providing long-term value.”
Mr. Chan Heng Fai, the Chairman of Document Security Systems, who owns Impact BioMedical, said that today’s announcement highlights Equivir’s potential versatility. “We are pleased to receive this second patent and are excited to explore the potential and long-term impact that Equivir can have on the way we treat and defend against these viruses.”
Equivir is believed to function by impeding a virus’s ability to infect and replicate in host cells. Taken much like a multivitamin, Equivir was specifically designed for ease of rapid accessibility and deployment. Pre-clinical in-vitro success showed Equivir is potentially useful for pandemics and viral outbreaks against SARS-COV2, Influenza, Ebola, Cholera, and Rhinovirus.
Ebola, also known as Ebola Virus Disease (EVD) or Ebola Hemorrhagic fever (EHF), is a rare but severe and often fatal illness in humans, particularly in sub-Saharan Africa. Ebola has a death rate of up to 90 percent, according to the World Health Organization. Rhinovirus is the most common viral infectious agent in humans and is the predominant cause of the common cold.
“Equivir is designed to address emerging viral epidemics and pandemics. This latest patent will support our research to explore Equivir as a deployable strategic defense for a broad spectrum of viral infections,” said Daryl Thompson, Impact BioLife's Director of Scientific Initiatives and founder of advanced research company GRDG Sciences, LLC ("GRDG"). Impact BioLife is a wholly owned subsidiary of Impact BioMedical.
The positive results achieved from initial studies makes it potentially valuable around the world, according to GRDG Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., United States Assistant Surgeon General (Retired) and former Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention. “We will continue to study the ways Equivir can lessen the severity of dangerous pathogens that affect populations all over the world. Whether it is used alongside other medications, or becomes the basis of its own therapeutic regimen, we are hopeful that Equivir can play a central role in impeding the spread of viruses,” said Dr. Moore.
Impact BioMedical reports that it has a third Equivir patent pending which contains claims directed to a method of limiting the occurrence of, reducing the risk or severity of, or treating other viral infections. Impact BioMedical has also completed a research study which evaluated the potential effectiveness of Equivir in in-vitro studies inhibiting viral infections including SARS-COV2.
About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of
For more information on DSS visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
FAQ
What recent patent was issued to DSS related to Equivir?
What diseases does Equivir target according to the press release?
What are the future plans for Equivir mentioned in the press release?
Who commented on Equivir's potential impact in the press release?
What is the significance of the pre-clinical results for Equivir?
